Mouse PD-L1/B7-H1 Antibody

Catalog # Availability Size / Price Qty
AF1019
AF1019-SP

Save 15% on Select RUO Reagents. See Details

Detection of Mouse PD-L1/B7-H1 by Western Blot.
10 Images
Product Details
Citations (70)
FAQs
Supplemental Products
Reviews (10)

Mouse PD-L1/B7-H1 Antibody Summary

Species Reactivity
Mouse
Specificity
Detects mouse PD-L1/B7-H1 in direct ELISAs and Western blots.
Source
Polyclonal Goat IgG
Purification
Antigen Affinity-purified
Immunogen
Mouse myeloma cell line NS0-derived recombinant mouse PD-L1/B7-H1
Phe19-Thr238
Accession # Q9EP73
Formulation
Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. See Certificate of Analysis for details.
*Small pack size (-SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
Label
Unconjugated

Applications

Recommended Concentration
Sample
Western Blot
0.5 µg/mL
See below
Flow Cytometry
0.25 µg/106 cells
See below
Immunohistochemistry
5-15 µg/mL
Perfusion fixed frozen sections of mouse small intestine (Peyer's patch) and thymus
CyTOF-ready
Ready to be labeled using established conjugation methods. No BSA or other carrier proteins that could interfere with conjugation.
 
Dual RNAscope ISH-IHC
5-15 µg/mL
Immersion fixed paraffin-embedded sections of mouse intestine

Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.

Scientific Data

Western Blot Detection of Mouse PD-L1/B7-H1 antibody by Western Blot. View Larger

Detection of Mouse PD-L1/B7-H1 by Western Blot. Western blot shows lysates of RAW 264.7 mouse monocyte/macrophage cell line untreated (-) or treated (+) with 10 µg/mL LPS for 4 hours. PVDF membrane was probed with 0.5 µg/mL of Goat Anti-Mouse PD-L1/B7-H1 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF1019) followed by HRP-conjugated Anti-Goat IgG Secondary Antibody (Catalog # HAF017). A specific band was detected for PD-L1/B7-H1 at approximately 50-55 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 1.

Flow Cytometry Detection of PD-L1/B7-H1 antibody in RAW 264.7 Mouse Cell Line antibody by Flow Cytometry. View Larger

Detection of PD-L1/B7-H1 in RAW 264.7 Mouse Cell Line by Flow Cytometry. RAW 264.7 mouse monocyte/macrophage cell line either treated with LPS overnight (filled histogram) or untreated (open histogram) was stained with Goat Anti-Mouse PD-L1/B7-H1 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF1019), followed by Allophycocyanin-conjugated Anti-Goat IgG Secondary Antibody (Catalog # F0108). View our protocol for Staining Membrane-associated Proteins.

Flow Cytometry Detection of PD-L1/B7-H1 antibody in HEK293 Human Cell Line Transfected with Mouse PD-L1/B7-H1 and eGFP antibody by Flow Cytometry. View Larger

Detection of PD-L1/B7-H1 in HEK293 Human Cell Line Transfected with Mouse PD-L1/B7-H1 and eGFP by Flow Cytometry. HEK293 human embryonic kidney cell line transfected with either (A) mouse PD-L1/B7-H1 or (B) irrelevant transfectants and eGFP was stained with Goat Anti-Mouse PD-L1/B7-H1 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF1019) followed by Allophycocyanin-conjugated Anti-Goat IgG Secondary Antibody (Catalog # F0108). Quadrant markers were set based on control antibody staining (Catalog # AB-108-C). View our protocol for Staining Membrane-associated Proteins.

Western Blot Detection of Mouse PD-L1 by Western Blot View Larger

Detection of Mouse PD-L1 by Western Blot Pyruvate kinase isoform M2 (PKM2) is required for LPS-induced expression of PD-L1. RAW cells (0.5 × 106 cells/ml) (A), bone marrow-derived macrophages (BMDMs) (B), or bone marrow-derived dendritic cells (C) were treated with TEPP-46 at 50 µM for 1 h prior to stimulation with LPS (100 ng/ml, 24 h), lysed and assayed for expression of PD-L1 by flow cytometry [(A–C) top panels] and pdl1 mRNA by RT-PCR [(A,B) bottom panels]. Statistical analysis was performed on cells from three separate experiments. Error bars represent mean ± SEM. BMDM cells were transfected with scrambled control (SC) or anti-PKM2 siRNA (D). 24 h post-transfection, cells were stimulated with LPS (100 ng/ml) for 24 h after which expression of PKM2 (top panel) and PDL1 (middle panel) was measured by western blot. Image collected and cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/29081778), licensed under a CC-BY license. Not internally tested by R&D Systems.

In-situ Hybridization View Larger

Detection of PD-L1/B7-H1 in Mouse Intestine. Formalin-fixed paraffin-embedded tissue sections of mouse intestines were probed for PD-L1 mRNA (ACD RNAScope Probe, catalog #420508; Fast Red chromogen, ACD catalog # 322750). Adjacent tissue section was processed for immunohistochemistry using goat anti-mouse PD-L1 polyclonal antibody (R&D Systems catalog # AF1019) at 3ug/mL with one-hour incubation at room temperature followed by incubation with anti-goat IgG VisUCyte HRP Polymer Antibody (Catalog # VC004) and DAB chromogen (yellow-brown). Tissue was counterstained with hematoxylin (blue). Specific staining was localized to lamina propria of villi.

Immunohistochemistry Detection of Mouse Mouse PD-L1/B7-H1 Antibody by Immunohistochemistry View Larger

Detection of Mouse Mouse PD-L1/B7-H1 Antibody by Immunohistochemistry Protumor roles for TAMs and granulocytic myeloid-derived suppressor cells are obviated in neoantigen+ PDA.(A) Immunofluorescence staining of CB+ (nAg+) or CB– (nAg–) orthotopic tumors on day 21. Arrows show CD8+ T cell contact with a macrophage. Scale bar: 50 μm. Original magnification of insets, 2.25×. The number of CD8+ T cell and TAM (F4/80+) contacts per field of view. The box plots depict the minimum and maximum values (whiskers), the upper and lower quartiles, and the median. The length of the box represents the interquartile range. Image collected and cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/35393950), licensed under a CC-BY license. Not internally tested by R&D Systems.

Immunohistochemistry Detection of Mouse Mouse PD-L1/B7-H1 Antibody by Immunohistochemistry View Larger

Detection of Mouse Mouse PD-L1/B7-H1 Antibody by Immunohistochemistry Representative images (×20 magnification) of H&E and PD-L1 IHC-stained sections (A-C): (A) Nude mouse lymph node showing normal histology (H&E) and diffuse staining for PD-L1 (mouse) with vessels and cells within the paracortical regions displaying increased staining intensity; (B) Nude mouse spleen showing normal histology (H&E) and intense membranous staining for PD-L1 (mouse) with the most intense staining at the periphery of the white pulp; (C) MDA-MB231 tumor showing a viable region (H&E necrotic regions were observed in all sections) with membranous and cytoplasmic staining for PD-L1 (human) on the tumor cells; (D) IHC quantitative analysis (staining intensity score, H-score) of PD-L1 expression levels in lymph nodes, spleen, and MDA-MB231 tumors from mouse xenografts; each bar represents the mean H-score ± standard deviation (SD; n = 3, spleen and lymph nodes; n= 6, tumors). Image collected and cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/31044647), licensed under a CC-BY license. Not internally tested by R&D Systems.

Immunohistochemistry Detection of Mouse Mouse PD-L1/B7-H1 Antibody by Immunohistochemistry View Larger

Detection of Mouse Mouse PD-L1/B7-H1 Antibody by Immunohistochemistry Representative images (×20 magnification) of H&E and PD-L1 IHC-stained sections (A-C): (A) Nude mouse lymph node showing normal histology (H&E) and diffuse staining for PD-L1 (mouse) with vessels and cells within the paracortical regions displaying increased staining intensity; (B) Nude mouse spleen showing normal histology (H&E) and intense membranous staining for PD-L1 (mouse) with the most intense staining at the periphery of the white pulp; (C) MDA-MB231 tumor showing a viable region (H&E necrotic regions were observed in all sections) with membranous and cytoplasmic staining for PD-L1 (human) on the tumor cells; (D) IHC quantitative analysis (staining intensity score, H-score) of PD-L1 expression levels in lymph nodes, spleen, and MDA-MB231 tumors from mouse xenografts; each bar represents the mean H-score ± standard deviation (SD; n = 3, spleen and lymph nodes; n= 6, tumors). Image collected and cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/31044647), licensed under a CC-BY license. Not internally tested by R&D Systems.

Immunohistochemistry Detection of Mouse Mouse PD-L1/B7-H1 Antibody by Immunohistochemistry View Larger

Detection of Mouse Mouse PD-L1/B7-H1 Antibody by Immunohistochemistry Representative images (×20 magnification) of H&E and PD-L1 IHC-stained sections (A-C): (A) Nude mouse lymph node showing normal histology (H&E) and diffuse staining for PD-L1 (mouse) with vessels and cells within the paracortical regions displaying increased staining intensity; (B) Nude mouse spleen showing normal histology (H&E) and intense membranous staining for PD-L1 (mouse) with the most intense staining at the periphery of the white pulp; (C) MDA-MB231 tumor showing a viable region (H&E necrotic regions were observed in all sections) with membranous and cytoplasmic staining for PD-L1 (human) on the tumor cells; (D) IHC quantitative analysis (staining intensity score, H-score) of PD-L1 expression levels in lymph nodes, spleen, and MDA-MB231 tumors from mouse xenografts; each bar represents the mean H-score ± standard deviation (SD; n = 3, spleen and lymph nodes; n= 6, tumors). Image collected and cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/31044647), licensed under a CC-BY license. Not internally tested by R&D Systems.

Immunocytochemistry/ Immunofluorescence Detection of Human PD-L1 by Immunocytochemistry/ Immunofluorescence View Larger

Detection of Human PD-L1 by Immunocytochemistry/ Immunofluorescence Human pancreas tissue from type 1 diabetic subjects express PD-L1. Human pancreas sections from type 1 diabetic (T1D), autoantibody positive (AA+), type 2 diabetic (T2D), and non-diabetic controls (NDB) were obtained from the Network for Pancreatic Organ Donation (nPOD) and stained for T cell markers (CD4, CD8), insulin, and PD-L1. Shown are representative islets from each group with 7–15 unique islets analyzed from three independent experiments with one patient per group. Scale bar corresponds to 20 µm. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/29844327), licensed under a CC-BY license. Not internally tested by R&D Systems.

Reconstitution Calculator

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Preparation and Storage

Reconstitution
Reconstitute at 0.2 mg/mL in sterile PBS. For liquid material, refer to CoA for concentration.
Loading...
Shipping
Lyophilized product is shipped at ambient temperature. Liquid small pack size (-SP) is shipped with polar packs. Upon receipt, store immediately at the temperature recommended below.
Stability & Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: PD-L1/B7-H1

Mouse B7 homolog 1(B7-H1), also called programmed death ligand 1 (PD-L1) and programmed cell death 1 ligand 1 (PDCD1L1), is a member of the B7 family of proteins that provide signals for regulating T-cell activation and tolerance (1‑4). Other family members include B7-1, B7-2, B7-H2, B7-H3 and PD-L2. B7 proteins are immunoglobulin (Ig) superfamily members with extracellular Ig-V-like and Ig-C-like domains and a short cytoplasmic region. Among the family members, they share from 20‑40% amino acid (aa) sequence identity. The cloned mouse B7-H1/PD-L1 cDNA encodes a 290 aa type I membrane precursor protein with a putative 18 aa signal peptide, a 220 aa extracellular region containing one V-like and one C-like Ig domain, a 22 aa transmembrane region, and a 30 aa cytoplasmic domain. Mouse and human B7-H1/PD-L1 share approximately 70% aa sequence identity. B7-H1/PD-L1 is one of two ligands for programmed death-1 (PD-1), a member of the CD28 family of immunoreceptors. The other identified ligand is PD-L2. Mouse B7-H1/PD-L1 and PD-L2 share approximately 34% aa sequence identity and have similar functions. B7-H1/PD-L1 is constitutively expressed in various lymphoid and non-lymphoid organs including placenta, heart, pancreas, lung, liver, and endothelium (1‑4). The expression of B7-H1/PD-L1 is detected on B cells, T cells, monocytes, dendritic cells and thymic epithelial cells. IFN-gamma treatment induces B7‑H1/PD‑L1 expression in monocytes, dendritic cells, and endothelial cells. B7-H1/PD-L1 expression is also upregulated in a variety of tumor cell lines. On previously activated T cells, B7-H1/PD-L1 interaction with PD-1 inhibits TCR-mediated proliferation and cytokine production, suggesting an inhibitory role in regulating immune responses. In contrast, a costimulatory function for the PD-1 ligands on resting T cells has also been reported (1‑4).

References
  1. Tamura, H. et al. (2001) Blood 97:1809.
  2. Freeman, G. et al. (2000) J. Exp. Med. 192:1027.
  3. Sharpe, A.H. and G. J. Freeman (2002) Nat. Rev. Immunol. 2:116.
  4. Coyle, A. and J. Gutierrez-Ramos (2001) Nat. Immunol. 2:203.
Long Name
Programmed Death Ligand 1
Entrez Gene IDs
29126 (Human); 60533 (Mouse); 499342 (Rat); 574058 (Porcine); 484186 (Canine); 102145573 (Cynomolgus Monkey)
Alternate Names
Avelumab; B7-H; B7H1; B7-H1; B7H1PDCD1L1; CD274 antigenMGC142294; CD274 molecule; CD274; PDCD1L1; PDCD1LG1; PDCD1LG1MGC142296; PDL1; PD-L1; PD-L1B7 homolog 1; PDL1PDCD1 ligand 1; programmed cell death 1 ligand 1; Programmed death ligand 1

Product Datasheets

You must select a language.

x

Citations for Mouse PD-L1/B7-H1 Antibody

R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.

70 Citations: Showing 1 - 10
Filter your results:

Filter by:

  1. NF-kappaB Activator 1 downregulation in macrophages activates STAT3 to promote adenoma-adenocarcinoma transition and immunosuppression in colorectal cancer
    Authors: S Wang, Y Kuai, S Lin, L Li, Q Gu, X Zhang, X Li, Y He, S Chen, X Xia, Z Ruan, C Lin, Y Ding, Q Zhang, C Qi, J Li, X He, JL Pathak, W Zhou, S Liu, L Wang, L Zheng
    Bmc Medicine, 2023-03-29;21(1):115.
  2. HDAC inhibition unlocks tumor plasticity and enhances immunotherapy response in Myc-Driven Small Cell Lung Cancer
    Authors: Ghafoor, A;Zhu, L;Ohler, ZW;Meskini, RE;Atkinson, D;Day, A;Bassel, L;Wang, W;Ying, H;Calvo, KR;Pongor, L;Pommier, Y;Thomas, A;Sun, Y;
    bioRxiv : the preprint server for biology
    Species: Mouse
    Sample Types: Whole Tissue
    Applications: Immunohistochemistry
  3. Citrullinated ENO1 Vaccine Enhances PD-1 Blockade in Mice Implanted with Murine Triple-Negative Breast Cancer Cells
    Authors: León-Letelier, RA;Sevillano-Mantas, AM;Chen, Y;Park, S;Vykoukal, J;Fahrmann, JF;Ostrin, EJ;Garrett, C;Dou, R;Cai, Y;Hsiao, FC;Dennison, JB;Vilar, E;Arun, BK;Hanash, S;Katayama, H;
    Vaccines
    Species: Mouse
    Sample Types: Whole Tissue
    Applications: Immunohistochemistry
  4. Adeno-associated virus-clustered regularly interspaced short palindromic repeats/cas9?mediated ovarian cancer treatment targeting PD-L1
    Authors: Yahata, T;Toujima, S;Sasaki, I;Iwahashi, N;Fujino, M;Nishioka, K;Noguchi, T;Tanizaki-Horiuchi, Y;Kaisho, T;Ino, K;
    BMC cancer
    Species: Mouse
    Sample Types: Cell Lysates
    Applications: Western Blot
  5. Disease-specific suppressive granulocytes participate in glioma progression
    Authors: Zhao, J;Wu, D;Liu, J;Zhang, Y;Li, C;Zhao, W;Cao, P;Wu, S;Li, M;Li, W;Liu, Y;Huang, Y;Cao, Y;Sun, Y;Yang, E;Ji, N;Yang, J;Chen, J;
    Cell reports
    Species: Mouse
    Sample Types: Whole Tissue
    Applications: Immunohistochemistry
  6. Epithelial-mesenchymal transition induced by tumor cell-intrinsic PD-L1 signaling predicts a poor response to immune checkpoint inhibitors in PD-L1-high lung cancer
    Authors: Jeong, H;Koh, J;Kim, S;Song, SG;Lee, SH;Jeon, Y;Lee, CH;Keam, B;Lee, SH;Chung, DH;Jeon, YK;
    British journal of cancer
    Species: Human
    Sample Types: Cell Lysates
    Applications: Western Blot
  7. A novel retinoic acid receptor-? agonist antagonizes immune checkpoint resistance in lung cancers by altering the tumor immune microenvironment
    Authors: Wei CH, Huang L, Kreh B et al.
    Sci Rep
  8. Design, synthesis, and biological activity of dual monoamine oxidase A and heat shock protein 90 inhibitors, N-Methylpropargylamine-conjugated 4-isopropylresorcinol for glioblastoma
    Authors: Tseng, HJ;Banerjee, S;Qian, B;Lai, MJ;Wu, TY;Hsu, TI;Lin, TE;Hsu, KC;Chuang, KH;Liou, JP;Shih, JC;
    European journal of medicinal chemistry
    Species: Mouse
    Sample Types: Whole Cells
    Applications: Flow Cytometry
  9. Tryptophan metabolism promotes immune evasion in human pancreatic beta cells
    Authors: Rachdi, L;Zhou, Z;Berthault, C;Lourenço, C;Fouque, A;Domet, T;Armanet, M;You, S;Peakman, M;Mallone, R;Scharfmann, R;
    EBioMedicine
    Species: Human
    Sample Types: Cell Lysates
    Applications: Western Blot
  10. CDK4/6 inhibitors and the pRB-E2F1 axis suppress PVR and PD-L1 expression in triple-negative breast cancer
    Authors: Shrestha, M;Wang, DY;Ben-David, Y;Zacksenhaus, E;
    Oncogenesis
    Species: Mouse
    Sample Types: Cell Lysates
    Applications: Western Blot
  11. Macrophages facilitate tumor cell PD‐L1 expression via an IL‐1 beta ‐centered loop to attenuate immune checkpoint blockade
    Authors: Cheng Xu, Yu Xia, Bai‐Wei Zhang, Emmanuel Kwateng Drokow, Hua‐Yi Li, Sen Xu et al.
    MedComm (2020)
  12. Angiogenic inhibitor pre-administration improves the therapeutic effects of immunotherapy
    Authors: M Sato, N Maishi, Y Hida, A Yanagawa-M, MT Alam, J Sakakibara, JM Nam, Y Onodera, S Konno, K Hida
    Cancer Medicine, 2023-02-19;0(0):.
    Species: Mouse
    Sample Types: Whole Tissue
    Applications: IHC
  13. Mevalonate improves anti-PD-1/PD-L1 efficacy by stabilizing CD274 mRNA
    Authors: Zhang, W;Pan, X;Xu, Y;Guo, H;Zheng, M;Chen, X;Wu, H;Luan, F;He, Q;Ding, L;Yang, B;
    Acta Pharmaceutica Sinica B
    Species: Human
    Sample Types: Cell Lysates
    Applications: Western Blot
  14. Pancreatic Islet Cells Response to IFNgamma Relies on Their Spatial Location within an Islet
    Authors: M De Burghgr, C Lourenço, C Berthault, V Aiello, A Villalba, A Fouque, M Diedisheim, S You, M Oshima, R Scharfmann
    Cells, 2022-12-28;12(1):.
    Species: Mouse
    Sample Types: Whole Tissue
    Applications: IHC
  15. Breast cancer cells survive chemotherapy by activating targetable immune modulatory programs characterized by either PD-L1 or CD80
    Authors: Ashkan Shahbandi, Fang-Yen Chiu, Nathan A. Ungerleider, Raegan Kvadas, Zeinab Mheidly, Meijuan J. S. Sun et al.
    Nature Cancer
  16. Multiscale imaging of therapeutic anti-PD-L1 antibody localization using molecularly defined imaging agents
    Authors: Iris M. Hagemans, Peter J. Wierstra, Kas Steuten, Janneke D. M. Molkenboer-Kuenen, Duco van Dalen, Martin ter Beest et al.
    Journal of Nanobiotechnology
  17. The expression of PD-1 ligand 1 on macrophages and its clinical impacts and mechanisms in lung adenocarcinoma
    Authors: Yusuke Shinchi, Shiho Ishizuka, Yoshihiro Komohara, Eri Matsubara, Remi Mito, Cheng Pan et al.
    Cancer Immunology, Immunotherapy
  18. Lentiviral interferon: A novel method for gene therapy in bladder cancer
    Authors: Sharada Mokkapati, Vikram M. Narayan, Ganiraju C. Manyam, Amy H. Lim, Jonathan J. Duplisea, Andrea Kokorovic et al.
    Molecular Therapy - Oncolytics
  19. WEE1 inhibition enhances the antitumor immune response to PD-L1 blockade by the concomitant activation of STING and STAT1 pathways in SCLC
    Authors: Hirokazu Taniguchi, Rebecca Caeser, Shweta S. Chavan, Yingqian A. Zhan, Andrew Chow, Parvathy Manoj et al.
    Cell Reports
  20. Inhibiting MNK kinases promotes macrophage immunosuppressive phenotype to limit CD8+ T cell anti-tumor immunity
    Authors: TN Pham, C Spaulding, MA Shields, AE Metropulos, DN Shah, MG Khalafalla, DR Principe, DJ Bentrem, HG Munshi
    JCI Insight, 2022-05-09;0(0):.
    Species: Mouse
    Sample Types: Whole Cell
    Applications: Western Blot
  21. Activation of Host-NLRP3 Inflammasome in Myeloid Cells Dictates Response to Anti-PD-1 Therapy in Metastatic Breast Cancers
    Authors: Isak W. Tengesdal, Suzhao Li, Nicholas E. Powers, Makenna May, Charles P. Neff, Leo A. B. Joosten et al.
    Pharmaceuticals (Basel)
  22. A novel multifunctional anti-PD-L1-CD16a-IL15 induces potent cancer cell killing in PD-L1-positive tumour cells
    Authors: Y Li, L Wu, Y Liu, S Ma, B Huang, X Feng, H Wang
    Translational Oncology, 2022-04-26;21(0):101424.
    Species: Mouse
    Sample Types: Recombinant Protein
    Applications: ELISA
  23. Mitogen-Activated Protein Kinase Phosphatase-1 Controls PD-L1 Expression by Regulating Type I Interferon during Systemic Escherichia coli Infection
    Authors: TJ Barley, PR Murphy, X Wang, BA Bowman, JM Mormol, CE Mager, SG Kirk, CJ Cash, SC Linn, X Meng, LD Nelin, B Chen, M Hafner, J Zhang, Y Liu
    The Journal of Biological Chemistry, 2022-04-13;0(0):101938.
    Species: Mouse
    Sample Types: Cell Lysates
    Applications: Western Blot
  24. PD-L1 Antibody Pharmacokinetics and Tumor Targeting in Mouse Models for Infectious Diseases
    Authors: Gerwin G. W. Sandker, Gosse Adema, Janneke Molkenboer-Kuenen, Peter Wierstra, Johan Bussink, Sandra Heskamp et al.
    Frontiers in Immunology
    Species: Mouse
    Sample Types: Whole Tissue
    Applications: Immunohistochemistry
  25. PD-L1 near Infrared Photoimmunotherapy of Ovarian Cancer Model
    Authors: J Jin, I Sivakumar, Y Mironchik, B Krishnamac, F Wildes, JD Barnett, CF Hung, S Nimmagadda, H Kobayashi, ZM Bhujwalla, MF Penet
    Cancers, 2022-01-26;14(3):.
    Species: Mouse
    Sample Types: Cell Lysates
    Applications: Western Blot
  26. SKI‐G‐801, an AXL kinase inhibitor, blocks metastasis through inducing anti‐tumor immune responses and potentiates anti‐PD‐1 therapy in mouse cancer models
    Authors: Chun‐Bong Synn, Sung Eun Kim, Hee Kyu Lee, Min‐Hwan Kim, Jae Hwan Kim, Ji Min Lee et al.
    Clinical & Translational Immunology
  27. Anti?VEGF antibody triggers the effect of anti?PD?L1 antibody in PD?L1low and immune desert?like mouse tumors
    Authors: N Ishikura, M Sugimoto, K Yorozu, M Kurasawa, O Kondoh
    Oncology reports, 2021-12-27;47(2):.
    Species: Mouse
    Sample Types: Whole Tissue
    Applications: IHC
  28. A Novel Kinase Inhibitor AX-0085 Inhibits Interferon-gamma-Mediated Induction of PD-L1 Expression and Promotes Immune Reaction to Lung Adenocarcinoma Cells
    Authors: J Kim, H Jang, GJ Lee, Y Hur, J Keum, JK Jo, SE Yun, SJ Park, YJ Park, MJ Choi, KS Kim, J Kim
    Cells, 2021-12-22;11(1):.
    Species: Human
    Sample Types: Cell Lysates
    Applications: Western Blot
  29. Loss of H2R signaling disrupts neutrophil homeostasis and promotes inflammation-associated colonic tumorigenesis in mice
    Authors: Z Shi, Y Mori-Akiya, W Du, R Fultz, Y Zhao, W Ruan, S Venable, MA Engevik, J Versalovic
    Cellular and Molecular Gastroenterology and Hepatology, 2021-11-13;0(0):.
    Species: Mouse
    Sample Types: Whole Tissue
    Applications: IHC
  30. Tumor-derived exosomes drive immunosuppressive macrophages in a pre-metastatic niche through glycolytic dominant metabolic reprogramming
    Authors: Samantha M. Morrissey, Fan Zhang, Chuanlin Ding, Diego Elias Montoya-Durango, Xiaoling Hu, Chenghui Yang et al.
    Cell Metabolism
    Species: Mouse
    Sample Types: Whole Cells
    Applications: Immunocytochemistry
  31. Distinct Biomarker Profiles and TCR Sequence Diversity Characterize the Response to PD-L1 Blockade in a Mouse Melanoma Model
    Authors: El Meskini R, Atkinson D, Kulaga A et al.
    Molecular Cancer Research
  32. Type 2 immunity is maintained during cancer-associated adipose tissue wasting
    Authors: Patrick J Lenehan, Assunta Cirella, Amiko M Uchida, Stephanie J Crowley, Tatyana Sharova, Genevieve Boland et al.
    Immunotherapy Advances
  33. Romidepsin (FK228) regulates the expression of the immune checkpoint ligand PD-L1 and suppresses cellular immune functions in colon cancer
    Authors: Yehui Shi, Ying Fu, Xin Zhang, Gang Zhao, Yuan Yao, Yan Guo et al.
    Cancer Immunology, Immunotherapy
  34. Immune receptor inhibition through enforced phosphatase recruitment
    Authors: RA Fernandes, L Su, Y Nishiga, J Ren, AM Bhuiyan, N Cheng, CJ Kuo, LK Picton, S Ohtsuki, RG Majzner, SP Rietberg, CL Mackall, Q Yin, LR Ali, X Yang, CS Savvides, J Sage, M Dougan, KC Garcia
    Nature, 2020-10-21;586(7831):779-784.
    Species: Mouse
    Sample Types: Whole Cells
    Applications: Flow Cytometry
  35. CD47 prevents the elimination of diseased fibroblasts in scleroderma
    Authors: T Lerbs, L Cui, ME King, T Chai, C Muscat, L Chung, R Brown, K Rieger, T Shibata, G Wernig
    JCI Insight, 2020-08-20;5(16):.
    Species: Mouse
    Sample Types: Whole Cells, Whole Tissue
    Applications: ICC, IHC
  36. Impacts of combining anti-PD-L1 immunotherapy and radiotherapy on the tumour immune microenvironment in a murine prostate cancer model
    Authors: Y Philippou, HT Sjoberg, E Murphy, S Alyacoubi, KI Jones, AN Gordon-Wee, S Phyu, EE Parkes, W Gillies Mc, AD Lamb, U Gileadi, V Cerundolo, DA Scheiblin, SJ Lockett, DA Wink, IG Mills, FC Hamdy, RJ Muschel, RJ Bryant
    Br. J. Cancer, 2020-07-09;0(0):.
    Species: Mouse
    Sample Types: Cell Lysates
    Applications: Western Blot
  37. Selective inhibition of HDAC3 targets synthetic vulnerabilities and activates immune surveillance in lymphoma.
    Authors: Patrizia Mondello, Saber Tadros, Matt Teater, Lorena Fontan, Aaron Y. Chang, Neeraj Jain et al.
    Cancer Discovery
  38. Degradation of tumour stromal hyaluronan by small extracellular vesicle-PH20 stimulates CD103+ dendritic cells and in combination with PD-L1 blockade boosts anti-tumour immunity
    Authors: Yeonsun Hong, Yoon Kyoung Kim, Gi Beom Kim, Gi-Hoon Nam, Seong A Kim, Yoon Park et al.
    Journal of Extracellular Vesicles
  39. Chimeric tumor modeling reveals role of partial PDL1 expression in resistance to virally induced immunotherapy
    Authors: Mee Y. Bartee, Parker C. Dryja, Eric Bartee
    Journal for ImmunoTherapy of Cancer
  40. The lytic activity of VSV-GP treatment dominates the therapeutic effects in a syngeneic model of lung cancer
    Authors: LM Schreiber, C Urbiola, K Das, B Spiesschae, J Kimpel, F Heinemann, B Stierstorf, P Müller, M Petersson, P Erlmann, D von Laer, G Wollmann
    Br. J. Cancer, 2019-09-18;0(0):.
    Species: Mouse
    Sample Types: Whole Tissue
    Applications: IHC-P
  41. Tumor Lymphatic Function Regulates Tumor Inflammatory and Immunosuppressive Microenvironments
    Authors: Raghu P. Kataru, Catherine L. Ly, Jinyeon Shin, Hyeung Ju Park, Jung Eun Baik, Sonia Rehal et al.
    Cancer Immunology Research
  42. IL-17C-mediated innate inflammation decreases the response to PD-1 blockade in a model of Kras-driven lung cancer
    Authors: F Ritzmann, C Jungnickel, G Vella, A Kamyschnik, C Herr, D Li, MM Menger, A Angenendt, M Hoth, A Lis, R Bals, C Beisswenge
    Sci Rep, 2019-07-17;9(1):10353.
    Species: Mouse
    Sample Types: Whole Tissue
    Applications: IHC-P
  43. Immunopotentiator Aikejia improves the therapeutic efficacy of PD-1/PD-L1 immunosuppressive pathway in CT26.WT cancer cell
    Authors: Chaoqun Huang, Xiaoqiong Tang, Suhuan Li, Qingshui Wang, Bifeng Xie, Jing Xu et al.
    Journal of Cancer
  44. Immuno-PET Imaging of the Programmed Cell Death-1 Ligand (PD-L1) Using a Zirconium-89 Labeled Therapeutic Antibody, Avelumab
    Authors: Elaine M. Jagoda, Olga Vasalatiy, Falguni Basuli, Ana Christina L. Opina, Mark R. Williams, Karen Wong et al.
    Mol Imaging
    Species: Mouse
    Sample Types: Whole Tissue
    Applications: Immunohistochemistry
  45. Programmed cell death ligand 1 d isruption by clustered regularly interspaced short palindromic repeats /Cas9‐genome editing promotes antitumor immunity and suppresses ovarian cancer progression
    Authors: Tamaki Yahata, Mika Mizoguchi, Akihiko Kimura, Takashi Orimo, Saori Toujima, Yumi Kuninaka et al.
    Cancer Science
  46. Non-Invasive Fluorescent Monitoring of Ovarian Cancer in an Immunocompetent Mouse Model
    Authors: Amy L. Wilson, Kirsty L. Wilson, Maree Bilandzic, Laura R. Moffitt, Ming Makanji, Mark D. Gorrell et al.
    Cancers (Basel)
  47. Adipose PD-L1 Modulates PD-1/PD-L1 Checkpoint Blockade Immunotherapy Efficacy in Breast Cancer
    Authors: Bogang Wu, Xiujie Sun, Harshita B. Gupta, Bin Yuan, Jingwei Li, Fei Ge et al.
    OncoImmunology
  48. Interferon-gamma drives programmed death-ligand 1 expression on islet ? cells to limit T cell function during autoimmune diabetes
    Authors: KC Osum, AL Burrack, T Martinov, NL Sahli, JS Mitchell, CG Tucker, KE Pauken, K Papas, B Appakalai, JA Spanier, BT Fife
    Sci Rep, 2018-05-29;8(1):8295.
    Species: Mouse
    Sample Types: Whole Tissue
    Applications: IHC
  49. PD-L1 checkpoint inhibition and anti-CTLA-4 whole tumor cell vaccination counter adaptive immune resistance: A mouse neuroblastoma model that mimics human disease
    Authors: P Srinivasan, X Wu, M Basu, C Rossi, AD Sandler
    PLoS Med., 2018-01-29;15(1):e1002497.
    Species: Mouse
    Sample Types: Whole Tissue
    Applications: IHC-P
  50. Programmed Cell Death Protein Ligand-1 (PD-L1) Silencing with Polyethylenimine-Dermatan Sulfate Complex for Dual Inhibition of Melanoma Growth
    Authors: Gijung Kwak, Dongkyu Kim, Gi-hoon Nam, Sun Young Wang, In-San Kim, Sun Hwa Kim et al.
    ACS Nano
    Species: Mouse
    Sample Types: Cell Lysates
    Applications: Western Blot
  51. Hormonal vitamin D upregulates tissue-specific PD-L1 and PD-L2 surface glycoprotein expression in human but not mouse
    Authors: V Dimitrov, M Bouttier, G Boukhaled, R Salehi-Tab, R Avramescu, B Memari, B Hasaj, GL Lukacs, CM Krawczyk, JH White
    J. Biol. Chem., 2017-10-23;0(0):.
    Species: Human
    Sample Types: Cell Lysates
    Applications: Western Blot
  52. Imaging of Programmed Cell Death Ligand 1: Impact of Protein Concentration on Distribution of Anti-PD-L1 SPECT Agents in an Immunocompetent Murine Model of Melanoma
    Authors: Jessie R. Nedrow, Anders Josefsson, Sunju Park, Sagar Ranka, Sanchita Roy, George Sgouros
    Journal of Nuclear Medicine
  53. Tumor localized secretion of soluble PD1 enhances oncolytic virotherapy
    Authors: MY Bartee, KM Dunlap, E Bartee
    Cancer Res, 2017-03-17;0(0):.
    Species: Mouse
    Sample Types: Cell Lysates
    Applications: Western Blot
  54. Dependence of Glomerulonephritis Induction on Novel Intraglomerular Alternatively Activated Bone Marrow-Derived Macrophages and Mac-1 and PD-L1 in Lupus-Prone NZM2328 Mice
    Authors: SJ Sung, Y Ge, C Dai, H Wang, SM Fu, R Sharma, YS Hahn, J Yu, TH Le, MD Okusa, WK Bolton, JR Lawler
    J. Immunol, 2017-02-20;0(0):.
    Species: Mouse
    Sample Types: Whole Cells, Whole Tissue
    Applications: Flow Cytometry, IHC
  55. Cell autonomous or systemic EGFR blockade alters the immune-environment in squamous cell carcinomas
    Int J Cancer, 2016-08-29;0(0):.
    Species: Mouse
    Sample Types: Whole Tissue
    Applications: IHC-P
  56. PD-1/PD-L1 blockade enhances T cell activity and antitumor efficacy of imatinib in gastrointestinal stromal tumors
    Clin Cancer Res, 2016-07-28;0(0):.
    Species: Mouse
    Sample Types: Whole Tissue
    Applications: IHC-P
  57. Systemic Immunotherapy of Non-Muscle Invasive Mouse Bladder Cancer with Avelumab, an Anti–PD-L1 Immune Checkpoint Inhibitor
    Authors: Amanda J. Vandeveer, Jonathan K. Fallon, Robert Tighe, Helen Sabzevari, Jeffrey Schlom, John W. Greiner
    Cancer Immunology Research
  58. IFN-gamma from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer.
    Authors: Abiko K, Matsumura N, Hamanishi J, Horikawa N, Murakami R, Yamaguchi K, Yoshioka Y, Baba T, Konishi I, Mandai M
    Br J Cancer, 2015-03-31;112(9):1501-9.
    Species: Mouse
    Sample Types: Tissue Homogenates, Whole Tissue
    Applications: IHC-Fr, Western Blot
  59. beta-Cell-targeted blockage of PD1 and CTLA4 pathways prevents development of autoimmune diabetes and acute allogeneic islets rejection.
    Authors: El Khatib M, Sakuma T, Tonne J, Mohamed M, Holditch S, Lu B, Kudva Y, Ikeda Y
    Gene Ther, 2015-03-19;22(5):430-8.
    Species: Human
    Sample Types: Cell Lysates
    Applications: Western Blot
  60. The development of endometrial hyperplasia in aged PD-1-deficient female mice
    Authors: Guoning Guo, Hong Li, Dayan Cao, Yongwen Chen
    Diagnostic Pathology
  61. PD-L1 Expression by Neurons Nearby Tumors Indicates Better Prognosis in Glioblastoma Patients
    Authors: Yawei Liu, Robert Carlsson, Malene Ambjorn, Maruf Hasan, Wiaam Badn, Anna Darabi et al.
    Journal of Neuroscience
  62. Cross-reactivity of anti-programmed death ligand 2 polyclonal antibody in mouse tissues
    Authors: Yu Zhao, GanLan Bian, CaiYong Yu, FangFang Liu, Ling Liu, HongMin Guo et al.
    Science China Life Sciences
  63. Endogenous retinoids in the pathogenesis of alopecia areata.
    Authors: Duncan F, Silva K, Johnson C, King B, Szatkiewicz J, Kamdar S, Ong D, Napoli J, Wang J, King L, Whiting D, McElwee K, Sundberg J, Everts H
    J Invest Dermatol, 2012-09-27;133(2):334-43.
    Species: Mouse
    Sample Types: Whole Tissue
    Applications: IHC
  64. Anti-programmed cell death 1 antibody reduces CD4+PD-1+ T cells and relieves the lupus-like nephritis of NZB/W F1 mice.
    Authors: Kasagi S, Kawano S, Okazaki T, Honjo T, Morinobu A, Hatachi S, Shimatani K, Tanaka Y, Minato N, Kumagai S
    J. Immunol., 2010-02-05;184(5):2337-47.
    Species: Mouse
    Sample Types: Whole Tissue
    Applications: IHC-Fr
  65. Altered availability of PD-1/PD ligands is associated with the failure to control autoimmunity in NOD mice.
    Authors: Yadav D, Hill N, Yagita H, Azuma M, Sarvetnick N
    Cell. Immunol., 2009-05-06;258(2):161-71.
    Species: Mouse
    Sample Types: Whole Tissue
    Applications: IHC-P
  66. Establishment of NOD-Pdcd1-/- mice as an efficient animal model of type I diabetes.
    Authors: Wang J, Yoshida T, Nakaki F, Hiai H, Okazaki T, Honjo T
    Proc. Natl. Acad. Sci. U.S.A., 2005-08-08;102(33):11823-8.
    Species: Mouse
    Sample Types: Whole Cells
    Applications: ICC
  67. Pyruvate Kinase M2 Is Required for the Expression of the Immune Checkpoint PD-L1 in Immune Cells and Tumors.
    Authors: Palsson-McDermott EM, Dyck L, Zastona Z et al.
    Front Immunol.
  68. Activation of G protein-coupled estrogen receptor signaling inhibits melanoma and improves response to immune checkpoint blockade
    Authors: Natale CA, Li J, Zhang J et al.
    Elife
  69. In situ immunogenic clearance induced by a combination of photodynamic therapy and rho-kinase inhibition sensitizes immune checkpoint blockade response to elicit systemic antitumor immunity against intraocular melanoma and its metastasis
    Authors: Kim S, Kim SA, Nam GH, et al.
    Journal for immunotherapy of cancer
  70. Burrack A, Spartz E, Raynor et al.
    Authors: Combination PD-1 and PD-L1 Blockade Promotes Durable Neoantigen-Specific T Cell-Mediated Immunity in Pancreatic Ductal Adenocarcinoma
    Cell Rep.

FAQs

No product specific FAQs exist for this product, however you may

View all Antibody FAQs
Loading...

Reviews for Mouse PD-L1/B7-H1 Antibody

Average Rating: 4.4 (Based on 10 Reviews)

5 Star
60%
4 Star
30%
3 Star
0%
2 Star
10%
1 Star
0%

Have you used Mouse PD-L1/B7-H1 Antibody?

Submit a review and receive an Amazon gift card.

$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Filter by:


Mouse PD-L1 Antibody
By Anonymous on 07/31/2020
Application: IHC Sample Tested: Breast cancer tissue Species: Mouse

Mouse PD-L1 Antibody
By Shubhankar Ambike on 01/21/2020
Application: Flow Sample Tested: MH-S mouse macrophage cell line,RAW 264.7 mouse monocyte/macrophage cell line Species: Mouse

MH-S and RAW264.7 cells were treated with 10ug/ml concentration of IFN alpha. Cells were analyzed by flow cytometer (surface staining) for PD-L1 expression using a labelled secondary antibody. Protocol was followed as given with the article. Worked exactly as expected.


Mouse PD-L1 Antibody
By Shubhankar Ambike on 12/31/2019
Application: WB Sample Tested: Cell Lysates Species: Mouse

MH-S mice macrophage cell lysates. Dark bands in the middle are PD-L1


Mouse PD-L1 Antibody
By Anonymous on 03/20/2019
Application: WB Sample Tested: HCT-116 human colorectal carcinoma cell line Species: Human

Mouse PD-L1 Antibody
By Dong Hu on 02/28/2019
Application: WB Sample Tested: mouse beast cancer cell line Eo771 Species: Mouse

Mouse PD-L1 Antibody
By Anonymous on 10/28/2018
Application: WB Sample Tested: 4T1 mouse breast cancer cell line,EMT6 cells Species: Mouse

Mouse PD-L1/B7-H1 Antibody
By Anonymous on 03/22/2018
Application: IHC Sample Tested: frozen section Species: Mouse

Mouse PD-L1/B7-H1 Antibody
By Angelo Taglialatela on 11/26/2017
Application: WB Sample Tested: cultured mouse mammary gland tumor,mouse mammary gland tumor cells Species: Mouse

Technical Service will be following up with the customer.


Mouse PD-L1/B7-H1 Antibody
By Purushottam Lamichhane on 10/17/2017
Application: IHC Sample Tested: Pancreas tissue Species: Mouse

Mouse B7‑H1/PD‑L1 Antibody
By Anonymous on 10/26/2015
Application: WB Sample Tested: Mouse lymphocytes Species: Mouse

Buffer: tbst
Dilution: 1/1000